Benign Prostate Hyperplasia Drugs Market, Global Outlook and Forecast 2022-2028

February 2022 | 60 pages | ID: B23FE43492E0EN
Market Monitor Global

Abstracts

The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.

This report contains market size and forecasts of Benign Prostate Hyperplasia Drugs in Global, including the following market information:

Global Benign Prostate Hyperplasia Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Benign Prostate Hyperplasia Drugs market was valued at 3425.9 million in 2021 and is projected to reach US$ 4258.9 million by 2028, at a CAGR of 3.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Alpha Blocker Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Benign Prostate Hyperplasia Drugs include Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals and Allergan and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Benign Prostate Hyperplasia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Benign Prostate Hyperplasia Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, by Type, 2021 (%)

• Alpha Blocker
• 5-Alpha Reductase Inhibitor
• Phosphodiesterase-5 Inhibitor
• Others

Global Benign Prostate Hyperplasia Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Other

Global Benign Prostate Hyperplasia Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Benign Prostate Hyperplasia Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Benign Prostate Hyperplasia Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Coloplast
• Pfizer
• Merck
• GlaxoSmithKline
• Eli Lilly and Company
• Abbott Laboratories
• Teva Pharmaceuticals
• Allergan
• Boehringer Ingelheim

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Benign Prostate Hyperplasia Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Benign Prostate Hyperplasia Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL BENIGN PROSTATE HYPERPLASIA DRUGS OVERALL MARKET SIZE

2.1 Global Benign Prostate Hyperplasia Drugs Market Size: 2021 VS 2028
2.2 Global Benign Prostate Hyperplasia Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Benign Prostate Hyperplasia Drugs Players in Global Market
3.2 Top Global Benign Prostate Hyperplasia Drugs Companies Ranked by Revenue
3.3 Global Benign Prostate Hyperplasia Drugs Revenue by Companies
3.4 Top 3 and Top 5 Benign Prostate Hyperplasia Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Benign Prostate Hyperplasia Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Benign Prostate Hyperplasia Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Benign Prostate Hyperplasia Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Benign Prostate Hyperplasia Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Benign Prostate Hyperplasia Drugs Market Size Markets, 2021 & 2028
  4.1.2 Alpha Blocker
  4.1.3 5-Alpha Reductase Inhibitor
  4.1.4 Phosphodiesterase-5 Inhibitor
  4.1.5 Others
4.2 By Type - Global Benign Prostate Hyperplasia Drugs Revenue & Forecasts
  4.2.1 By Type - Global Benign Prostate Hyperplasia Drugs Revenue, 2017-2022
  4.2.2 By Type - Global Benign Prostate Hyperplasia Drugs Revenue, 2023-2028
  4.2.3 By Type - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Benign Prostate Hyperplasia Drugs Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Other
5.2 By Application - Global Benign Prostate Hyperplasia Drugs Revenue & Forecasts
  5.2.1 By Application - Global Benign Prostate Hyperplasia Drugs Revenue, 2017-2022
  5.2.2 By Application - Global Benign Prostate Hyperplasia Drugs Revenue, 2023-2028
  5.2.3 By Application - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Benign Prostate Hyperplasia Drugs Market Size, 2021 & 2028
6.2 By Region - Global Benign Prostate Hyperplasia Drugs Revenue & Forecasts
  6.2.1 By Region - Global Benign Prostate Hyperplasia Drugs Revenue, 2017-2022
  6.2.2 By Region - Global Benign Prostate Hyperplasia Drugs Revenue, 2023-2028
  6.2.3 By Region - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Benign Prostate Hyperplasia Drugs Revenue, 2017-2028
  6.3.2 US Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.3.3 Canada Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.3.4 Mexico Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Benign Prostate Hyperplasia Drugs Revenue, 2017-2028
  6.4.2 Germany Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.3 France Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.4 U.K. Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.5 Italy Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.6 Russia Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.7 Nordic Countries Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.4.8 Benelux Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Benign Prostate Hyperplasia Drugs Revenue, 2017-2028
  6.5.2 China Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.5.3 Japan Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.5.4 South Korea Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.5.5 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.5.6 India Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Benign Prostate Hyperplasia Drugs Revenue, 2017-2028
  6.6.2 Brazil Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.6.3 Argentina Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue, 2017-2028
  6.7.2 Turkey Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.7.3 Israel Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.7.4 Saudi Arabia Benign Prostate Hyperplasia Drugs Market Size, 2017-2028
  6.7.5 UAE Benign Prostate Hyperplasia Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sanofi
  7.1.1 Sanofi Corporate Summary
  7.1.2 Sanofi Business Overview
  7.1.3 Sanofi Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.1.4 Sanofi Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.1.5 Sanofi Key News
7.2 Coloplast
  7.2.1 Coloplast Corporate Summary
  7.2.2 Coloplast Business Overview
  7.2.3 Coloplast Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.2.4 Coloplast Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.2.5 Coloplast Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.3.4 Pfizer Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 Merck
  7.4.1 Merck Corporate Summary
  7.4.2 Merck Business Overview
  7.4.3 Merck Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.4.4 Merck Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.4.5 Merck Key News
7.5 GlaxoSmithKline
  7.5.1 GlaxoSmithKline Corporate Summary
  7.5.2 GlaxoSmithKline Business Overview
  7.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.5.4 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.5.5 GlaxoSmithKline Key News
7.6 Eli Lilly and Company
  7.6.1 Eli Lilly and Company Corporate Summary
  7.6.2 Eli Lilly and Company Business Overview
  7.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.6.4 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.6.5 Eli Lilly and Company Key News
7.7 Abbott Laboratories
  7.7.1 Abbott Laboratories Corporate Summary
  7.7.2 Abbott Laboratories Business Overview
  7.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.7.4 Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.7.5 Abbott Laboratories Key News
7.8 Teva Pharmaceuticals
  7.8.1 Teva Pharmaceuticals Corporate Summary
  7.8.2 Teva Pharmaceuticals Business Overview
  7.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.8.4 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.8.5 Teva Pharmaceuticals Key News
7.9 Allergan
  7.9.1 Allergan Corporate Summary
  7.9.2 Allergan Business Overview
  7.9.3 Allergan Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.9.4 Allergan Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.9.5 Allergan Key News
7.10 Boehringer Ingelheim
  7.10.1 Boehringer Ingelheim Corporate Summary
  7.10.2 Boehringer Ingelheim Business Overview
  7.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Major Product Offerings
  7.10.4 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue in Global Market (2017-2022)
  7.10.5 Boehringer Ingelheim Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Benign Prostate Hyperplasia Drugs Market Opportunities & Trends in Global Market
Table 2. Benign Prostate Hyperplasia Drugs Market Drivers in Global Market
Table 3. Benign Prostate Hyperplasia Drugs Market Restraints in Global Market
Table 4. Key Players of Benign Prostate Hyperplasia Drugs in Global Market
Table 5. Top Benign Prostate Hyperplasia Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Benign Prostate Hyperplasia Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Benign Prostate Hyperplasia Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Benign Prostate Hyperplasia Drugs Product Type
Table 9. List of Global Tier 1 Benign Prostate Hyperplasia Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Benign Prostate Hyperplasia Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Benign Prostate Hyperplasia Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Benign Prostate Hyperplasia Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Benign Prostate Hyperplasia Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Benign Prostate Hyperplasia Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Benign Prostate Hyperplasia Drugs Product Offerings
Table 32. Sanofi Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Coloplast Corporate Summary
Table 34. Coloplast Benign Prostate Hyperplasia Drugs Product Offerings
Table 35. Coloplast Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Benign Prostate Hyperplasia Drugs Product Offerings
Table 38. Pfizer Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Merck Corporate Summary
Table 40. Merck Benign Prostate Hyperplasia Drugs Product Offerings
Table 41. Merck Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline Corporate Summary
Table 43. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product Offerings
Table 44. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Eli Lilly and Company Corporate Summary
Table 46. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product Offerings
Table 47. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Abbott Laboratories Corporate Summary
Table 49. Abbott Laboratories Benign Prostate Hyperplasia Drugs Product Offerings
Table 50. Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Teva Pharmaceuticals Corporate Summary
Table 52. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Product Offerings
Table 53. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Allergan Corporate Summary
Table 55. Allergan Benign Prostate Hyperplasia Drugs Product Offerings
Table 56. Allergan Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Boehringer Ingelheim Corporate Summary
Table 58. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product Offerings
Table 59. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Benign Prostate Hyperplasia Drugs Segment by Type in 2021
Figure 2. Benign Prostate Hyperplasia Drugs Segment by Application in 2021
Figure 3. Global Benign Prostate Hyperplasia Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Benign Prostate Hyperplasia Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Benign Prostate Hyperplasia Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2021
Figure 8. By Type - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 12. US Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 24. China Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Benign Prostate Hyperplasia Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Coloplast Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Allergan Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)